What is the current market valuation of the US transarterial chemoembolization market?

The market valuation was $2929.95 Million in 2024. Read More

What is the projected market size for the US transarterial chemoembolization market by 2035?

The projected market size is expected to reach $5000.0 Million by 2035. Read More

What is the expected CAGR for the US transarterial chemoembolization market during the forecast period 2025 - 2035?

The expected CAGR is 4.98% during the forecast period 2025 - 2035. Read More

Which procedure type generated the highest revenue in the US transarterial chemoembolization market?

Conventional TACE generated revenue between $2200.0 Million and $3500.0 Million. Read More

What are the key indications driving the US transarterial chemoembolization market?

Unresectable HCC and Early-Stage HCC are key indications, with revenues of $1750.0 Million to $3000.0 Million and $1179.95 Million to $2000.0 Million, respectively. Read More

Which product type is expected to contribute significantly to the US transarterial chemoembolization market?

Chemotherapeutic Agents are projected to generate revenue between $1170.0 Million and $2000.0 Million. Read More

What are the primary end users of transarterial chemoembolization in the US market?

Hospitals & Clinics are the primary end users, with revenues ranging from $1500.0 Million to $2500.0 Million. Read More

Who are the key players in the US transarterial chemoembolization market?

Key players include Boston Scientific, Medtronic, Bayer, Terumo Corporation, Cook Medical, Halyard Health, AngioDynamics, and Merit Medical Systems. Read More

What is the revenue range for drug-eluting particles in the US transarterial chemoembolization market?

Revenue for drug-eluting particles is expected to range from $700.0 Million to $1200.0 Million. Read More

How does the revenue for cancer research centers compare to other end users in the US transarterial chemoembolization market?

Cancer Research Centers are projected to generate revenue between $800.0 Million and $1500.0 Million, indicating a substantial contribution compared to other end users. Read More

US Transarterial Chemoembolization Market

US Transarterial Chemoembolization Market Research Report By Procedure Type (Conventional TACE, DEB-TACE), By Indication (Unresectable HCC, Early-Stage HCC), By Product Type (Chemotherapeutic Agents, Radiotherapeutic Agents, Drug-eluting Particles, Others) and By End User (Hospitals & Clinics, Cancer Research Centers, Others) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

4.98%

2024 Market Size

$ 2,929.95 Million

2035 Market Size

$ 5,000 Million

Healthcare ● Updated August 2026 Report ID: MRFR/HC/14854-HCR | Pages: 100 | Author: Satyendra Maurya, Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Pharmaceutical, BY Procedure Type (USD Million)
  1. 4.1.1 Conventional TACE
  2. 4.1.2 DEB-TACE
2. 4.2 Pharmaceutical, BY Indication (USD Million)
  1. 4.2.1 Unresectable HCC
  2. 4.2.2 Early-Stage HCC
3. 4.3 Pharmaceutical, BY Product Type (USD Million)
  1. 4.3.1 Chemotherapeutic Agents
  2. 4.3.2 Radiotherapeutic Agents
  3. 4.3.3 Drug-eluting Particles
  4. 4.3.4 Others
4. 4.4 Pharmaceutical, BY End User (USD Million)
  1. 4.4.1 Hospitals & Clinics
  2. 4.4.2 Cancer Research Centers
  3. 4.4.3 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Boston Scientific (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Medtronic (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bayer (DE)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Terumo Corporation (JP)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Cook Medical (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Halyard Health (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 AngioDynamics (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Merit Medical Systems (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY PROCEDURE TYPE
3. 6.3 US MARKET ANALYSIS BY INDICATION
4. 6.4 US MARKET ANALYSIS BY PRODUCT TYPE
5. 6.5 US MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
12. 6.12 PHARMACEUTICAL, BY PROCEDURE TYPE, 2024 (% SHARE)
13. 6.13 PHARMACEUTICAL, BY PROCEDURE TYPE, 2024 TO 2035 (USD Million)
14. 6.14 PHARMACEUTICAL, BY INDICATION, 2024 (% SHARE)
15. 6.15 PHARMACEUTICAL, BY INDICATION, 2024 TO 2035 (USD Million)
16. 6.16 PHARMACEUTICAL, BY PRODUCT TYPE, 2024 (% SHARE)
17. 6.17 PHARMACEUTICAL, BY PRODUCT TYPE, 2024 TO 2035 (USD Million)
18. 6.18 PHARMACEUTICAL, BY END USER, 2024 (% SHARE)
19. 6.19 PHARMACEUTICAL, BY END USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY PROCEDURE TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY INDICATION, 2025-2035 (USD Million)
  3. 7.2.3 BY PRODUCT TYPE, 2025-2035 (USD Million)
  4. 7.2.4 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Transarterial Chemoembolization Market Segmentation

US Transarterial Chemoembolization Market By Procedure Type (USD Million, 2025-2035)

Conventional TACE
DEB-TACE

US Transarterial Chemoembolization Market By Indication (USD Million, 2025-2035)

Unresectable HCC
Early-Stage HCC

US Transarterial Chemoembolization Market By Product Type (USD Million, 2025-2035)

Chemotherapeutic Agents
Radiotherapeutic Agents
Drug-eluting Particles
Others

US Transarterial Chemoembolization Market By End User (USD Million, 2025-2035)

Hospitals & Clinics
Cancer Research Centers
Others

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”